
|Articles|August 1, 2002
Phakic lens holds promise for correcting high myopia, hyperopia
Philadelphia-Patients with high myopia and high hyperopia seemed to have a good response to the implantation of the Phakic Refractive Lens (PRL, Medennium Inc.), according to Kenneth J. Hoffer, MD, who reported on the phase III trial for myopia and the phase II trial for hyperopia during the American Society of Cataract and Refractive Surgery meeting here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
2
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region
3
AAVantgarde Bio closes $141 million Series B financing round
4


















































.png)


